# RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of-2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Nicholas J. Robert,Véronique Dièras,John A. Glaspy,Adam Brufsky,Igor Bondarenko,Oleg Lipatov,Edith A. Perez,Denise A. Yardley,Xiaolei Zhou,Sem H. Phan |
| Citations | 140 |
| DOI | 10.1200/jco.2009.27.15_suppl.1005 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3081058368 |
| Type | conference-abstract |
| Year | 2009 |

## Paper authors

- [Xiaolei Zhou](https://scholariq.org/researchers/xiaolei-zhou/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Paper topics

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.